Huge Samsung BioLogics IPO Reflects Rosy Manufacturing Outlook
Executive Summary
Samsung BioLogics has successful floated in one of South Korea’s largest ever IPOs and appears to be on track to becoming the top global contract manufacturer of biologics amid rising demand from cost-conscious global clients.
You may also be interested in...
Samsung BioLogics Under Spotlight Over Accounting Handling Of Biogen JV
Samsung BioLogics shares plunge on suspicions it has violated accounting related to affiliate Samsung Bioepis, but the company says its accounting meets IFRS standards and denies any transgressions. Samsung BioLogics could face a penalty, depending on the outcome of upcoming financial authority meetings and whether Biogen exercises its call option on Samsung Bioepis in the coming months.
Samsung BioLogics Under Spotlight Over Accounting Handling Of Biogen JV
Samsung BioLogics shares plunge on suspicions it has violated accounting related to affiliate Samsung Bioepis, but the company says its accounting meets IFRS standards and denies any transgressions. Samsung BioLogics could face a penalty, depending on the outcome of upcoming financial authority meetings and whether Biogen exercises its call option on Samsung Bioepis in the coming months.
Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results
Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.